Compare iShares Core High Dividend ETF (HDV) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core High Dividend ETF vs Smith & Nephew plc — how do they compare? iShares Core High Dividend ETF trades at $29.08, while Smith & Nephew plc trades at $29.82 (market cap $12.54B). The key difference: Smith & Nephew plc pays a 2.65% dividend while iShares Core High Dividend ETF pays none, and iShares Core High Dividend ETF is trading nearer its 52-week high, Smith & Nephew plc nearer its low. Which is the better fit depends on your goals.
| HDV | SNN | |
|---|---|---|
52-Week High | $29.14 | $38.70 |
52-Week Low | $23.64 | $28.73 |
Market Cap | — | $12.54B |
Sector | — | Health |
Enterprise Value | — | $15.57B |
Dividend Yield | — | 2.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HDV trades at $29.04, up 0.17% with a bullish technical signal from moving averages. The ETF focuses on high-quality dividend stocks, delivering a 3.1% yield while outperforming the S&P 500 by 9 percentage points year-to-date. Recent institutional buying includes Bay Colony Advisors increasing holdings by 370.7% and 180 Wealth Advisors by 386.2% in Q2 2026. Technical indicators show strong momentum with RSI at 76.33 suggesting overbought conditions, while support and resistance cluster around $29.
HDV offers attractive income generation through quality dividend stocks, with defensive sector exposure providing stability. The ETF's screening methodology favors companies with sustainable dividends and strong balance sheets. Key risks include interest rate sensitivity and sector concentration in healthcare and energy. Current technical overbought conditions may limit near-term upside potential despite strong institutional interest.
Smith & Nephew (SNN) trades at $29.76, down 1.06% with bearish technical signals. The company shows improving fundamentals with revenue growth from $5.8B to $6.2B and net income margin expanding to 10.08% in 2025. Recent Q2 2026 earnings beat expectations but the company lowered full-year revenue guidance from 6% to 4% growth due to U.S. Orthopaedics weakness.
While valuation multiples appear reasonable (P/E 20.41, EV/EBITDA 9.9), the stock faces headwinds from mixed earnings performance and cautious analyst sentiment. The primary investment case hinges on execution in robotics and wound care segments offsetting orthopedic challenges, with downside risk from continued U.S. market softness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares Core High Dividend ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index is comprised of qualified income paying securities that are screened for superior company quality and financial health as determined by Morningstar, Inc.'s proprietary index methodology. The fund is non-diversified.
Read more on HDV →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
